Daniel Gonzalez H

Medicina Interna - Oncologia, Clinica Astorga - HSVFR

[MLP Oncología @MLPOncoData]

#medicalreversal seguimiento oncológico

[Diego Felipe Ballen @BallenDF]

After the breathtaking results presented at #ESMOGI26 on KRAS inhibitors, we hope @RevMedicines will include Latin America in its phase III trials and help ensure early access to these therapies across LMICs.

[Pietro Garlatti @PietroGarlatti]

Proud to share that ARTO trial long-term results are out in @TheLancetOncol! 📄✨
​In oligometCRPC, adding SBRT to abi+ADT significantly improves Overall Survival (HR 0.55, p=0.021). PFS 🎯 44 vs 17m!
@GiulioFrancoli1 @dicataldovanes1 @NiccolBertini2 @MicheleAquilano

[Tom Powles @tompowles1]

EMA approval of perioperative EVP in cisplatin ineligible muscle invasive bladder cancer occurred today.

This is a big step towards curing more patients

Extension to cisplatin eligible patients soon - we hope (based on +ve OS in B15 study)

Bladder surgery sparing trials next (EV209 and 309)

https://t.co/6f0wedUEXZ

[Paolo Tarantino @PTarantinoMD]

BREAKING: The most controversial article of the year, claiming that early morning immunotherapy works better than in the afternoon, is now retracted.

After reading the responses provided by the authors to the inconsistencies raised in the web, the @NatureMedicine editors no longer have confidence in the integrity of the results. The only prospective evidence that time-of-day matters for immunotherapy is now gone.

https://t.co/aXUY6aekhl

To me, this means (at least) two things.

First, it confirms that prudence on this topic was and remains critical. For as inexpensive it may be to give a drug earlier or later in the day, it carries a much more relevant cost: the one of scientific integrity. We owe our patients to make decisions based on solid data. We should not give up this practice too easily, particularly in the presence of several concerning red flags.

Second, this retraction should also prompt a broader reflection on the current state of peer review, in which unpaid reviewers struggle to keep up with a steady rise in submitted papers. Journals need to improve the process by implementing a formal, consistent, in-depth review of each paper by paid professionals. A practice that, in this case, may have avoided a retraction arriving after 22 citations and after inclusion of this study in at least one meta-analysis. And possibly, after some physicians had already changed their practice in IO administration.

For a thoughtful recap of this story, I recommend this well-written new piece in @ScienceMagazine by Laura Agudelo. I’m grateful to Laura for including my perspective in the article.

https://t.co/qHM5fMjwQ3

[Yakup Ergün @dr_yakupergun]

How to give a bad talk

https://t.co/O8IF7IW7Lv

[Paolo Tarantino @PTarantinoMD]

Here we go again @BalazsHalmosMD

[David González Escobar @dgonza97]

Municipios donde Iván Cepeda casi duplicó, triplicó y hasta quintuplicó su votación frene a primera vuelta. ¿Qué tendrán en común? Seguro nada sospechoso....

[MLP Oncología @MLPOncoData]

Los pacientes merecen algo mejor que lo que en estos 4 años les dieron (quitaron) Corcho, Jaramillo, Leal, Quintero, Ospina, etc…

[Daniel Gonzalez H @danielzgonzale]

@endocrinorosero Oscar almenos hace un mínimo esfuerzo
O pregúntale a notebook lm que ya es lo único que sabes hacer
Saludos

[Paolo Tarantino @PTarantinoMD]

The first study of scalp cooling for alopecia prevention with T-DXd is out in @ESMO_Open, conducted at @DFCI_BreastOnc

No clear signs of reduction in alopecia (55% G2 alopecia with/without scalp cooling)

Novel strategies for hair preservation with ADCs are under development

[Diego Felipe Ballen @BallenDF]

Una gran proporción del cáncer de colon puede ser prevenible o curable si se encuentra en etapas tempranas. https://t.co/KW6z7KBLbv

[Sara Tolaney @stolaney1]

Important study for q12wk denosumab c/w q4wk--> can give denosumab every 12 wks and have less toxicity and similar benefits

@OncoAlert #ASCO26

[Martin ZapataLaguado @zapatalaguadomd]

#ASCO26 PROTEUS HrLPC Beyond the positive MFS results, one important advance is the incorporation of PSMA-PET will this translate into an overall survival benefit? We eagerly await the OS results. For now a potential SOC @SCUColombia @achoHematoYOnco @OncoAlert @oncodaily @ASCO

[Toni Choueiri, MD @DrChoueiri]

Congrats to Dr Taplin, all @DanaFarber_GU @DanaFarber and #PROTEUS team on a new frontier in high-risk prostate cancer.

Now officially in @NEJM !

https://t.co/36dUY9OUBN

[Erman Akkus @Erman_Akkus]

🚀Daraxonrasib curves @NEJM 👇
2L of metastatic pancreatic cancer
#ASCO26

https://t.co/JuVXy9q39c

#cancer #oncology #pancreatic #MedX @OncoAlert @realbowtiedoc @DrVilmaPBarcia

[Paolo Tarantino @PTarantinoMD]

8-year results from KEYNOTE-522 presented by @JavierCortesMD. Adding perioperative pembro to neoadjuvant chemo prevents ~10% recurrences and ~7% deaths from TNBC. A tough neoadjuvant regimen, but one that clearly saves lives. No TILs data presented yet, unfortunately. #ASCO26

[Hope Rugo @hoperugo]

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer | New England Journal of Medicine https://t.co/OPgIQaK7PF

[Contraloría General de la República de Colombia @CGR_Colombia]

🚨Advertimos a la @Supersalud sobre el deterioro crítico y sostenido de las #EPS bajo intervención forzosa administrativa. El seguimiento realizado evidencia que las intervenciones no están cumpliendo su objetivo de estabilizar el sistema y que, en la mayoría de los casos, los pasivos aumentaron drásticamente desde la adopción de estas medidas.

📲Comunicado de prensa👉🏼 https://t.co/EjCYQBP4t9

[Dr Rishabh Jain @DrRishabhOnco]

🚨 FDA’s take on SERENA-6 is basically this:
“Nice data… but are we helping patients?”

Let’s break it down 👇

🧠 Problem 1: Wrong question

Trial asks:
👉 Switch early vs don’t switch

But real-world question is:
👉 Switch early vs switch later
FDA:
❌ “You didn’t answer the real question.”

⏱️ Problem 2: The PFS illusion

PFS looks great (16 vs 9.2 months)

But… it starts from:
👉 ESR1 mutation detection (not progression)

FDA:
❓ “What does this PFS even mean clinically?”

🧬 Problem 3: Biology mismatch

We assume: ESR1 mutation = resistance

FDA says:
👉 Not so fast

Patients may still benefit from AI + CDK4/6i
even AFTER mutation appears

👉 Early switch = stopping a working drug

🔁 Problem 4: No second chance

Control arm never got camizestrant later ❌

So we don’t know:
👉 Early vs delayed use

FDA:
❌ “This comparison is incomplete”

📉 Problem 5: Where is survival benefit?

OS = immature
Final data → years away

FDA:
👉 “Without OS, paradigm shift is risky”

⚠️ Problem 6: Not risk-free

QT prolongation
Bradycardia
Rare TdP

👉 Not a harmless switch

🎯 FDA’s real message:

“Just because we can act early…
doesn’t mean we should.”

🔖 Save this - this is how regulators think

📖 Full FDA briefing in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #ESMOBreast26
@OncoAlert @myesmo @esmo_open @asco @OncBrothers